DOCSLIB.ORG

2006 ICRS Symposium Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2006 ICRS Symposium Program Program and Abstracts 16TH ANNUAL SYMPOSIUM ON THE CANNABINOIDS Hotel Club Tihany Tihany, Hungary JUNE 24 – 28, 2006 Copyright© 2006 by the International Cannabinoid Research Society, Inc. Department of Psychology University of Vermont Burlington VT 05405 USA 05405 World Wide Web Site: http://www.cannabinoidsociety.org Logo by: Natalia Realini ISBN:09658053-0-8 These abstracts may be cited in the scientific literature. The citation format is as follows: Author(s), Abstract Title (2006) 16th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, page #. International Cannabinoid Research Society 2006 Symposium on the Cannabinoids June 24-28, Club Tihany Tihany, Hungary ICRS Symposium & Young Investigator Award Sponsor Sanofi-Aventis Sponsors GW Pharmaceuticals, Inc. Allergan, Inc. AstraZeneca R&D, Molndal Bristol-Myers Squibb Pharmaceutical Research Institute Cayman Chemical Company Eli Lilly & Company Elsohly Laboratories Gedeon Richter Pharmaceutical, Ltd., Hungary Merck & Co., Inc. – USA Pfizer, Inc. SIGMA-ALDRICH, Hungary Government Sponsors National Institute on Drug Abuse NIH – National Institute on Alcohol Abuse and Alcoholism Department of Drug Strategic Affairs, Ministry of Youth, Family, Social Affairs and Equal Opportunities, Hungary Ministry of Health, Hungary Health Canada Ambassade de France en Hongrie Non-Profit Organization Sponsors Kang Tsou Memorial Fund Sudden Cardiac Death Foundation, Hungary Academic Sponsors Semmelweis University Semmelweis Publisher University of Vermont Tourism Company Sponsors MALEV Air Tours Tourinform, Tihany Program Committee Daniela Parolaro Tiziana Bisogno Vincenzo Di Marzo Christopher Fowler Richard Musty Abstract and Program Coordinators Jason Schechter and Nicole Schechter Conference Planner Diane Mahadeen Local Conference Organizers Tibor Wenger, Semmelweis University, Budapest Zoltan Jarai, Semmelweis University, Budapest Gergely Cseplo, Semmelweis University Local Student Organizers Csilla Csikos, Balazs Dezsenyi, Krisztina Grosz, Melinda Kiss, Adam Kreisz, Mark Olah, Eszter Paldy and Daniel Szekacs Webmaster Jason Schechter ICRS Executive Committee Daniela Parolaro President Christopher Fowler President-Elect Vincenzo Di Marzo Past President Particia Reggio Secretary Roger Pertwee International Secretary Jenny Wiley Treasurer Richard Musty Executive Director Brian Thomas Executive Newsletter Editor Alessia Ligresti Student Representative 1166 th AAnnnnuuaall SSyymmppoossiiuumm OOnn TThhee CCaannnnaabbiinnooiiddss 2006 Program . Registration June 24, 2006 (1600-2000) Day 1 Sunday, June 25th 7.50 - 8.00 OPENING REMARKS Session 1. SAR Studies and New Synthetic Molecules ¾ Chairs: Drs. Brian Thomas and Raj Razdan Page # THE RELEVANCE OF THE STERIC FACTOR Yehoshua Maor, Ruth Gallily IN THE BIOLOGICAL ACTIVITY OF CBD 8.00 DERIVATIVES – 1 and Raphael Mechoulam A TOOL IN IDENTIFYING NOVEL MOLECULAR TARGET FOR CANNABINOIDS 1-PENTYL-2-ARYL-4-(1- John W. Huffman, Lea W. Padgett, NAPHTHOYL)PYRROLES: A NEW 2 Matthew L. Isherwood, Jenny L. Wiley 8.15 CLASS OF HIGH AFFINITY LIGANDS and Billy R. Martin FOR THE CB1 AND CB2 RECEPTORS T.M. Fong, L.S. Lin, X-M Guan, D.J. Marsh, C-P Shen, J. Lao, D.S. Stribling, K.M. Rosko, H. Yu, Y. Feng, J.C. Xiao , L.H.T. Van der Ploeg, M.T. Goulet, W.K. DISCOVERY OF A NOVEL CB1R 3 8.30 Hagmann, T.J. Lanza, Jr., J.P. Jewell, P. Liu, S.K. Shah, H. Qi, X. Tong, J. Wang, and S. Xu, R. Gibson, B. INVERSE AGONIST Francis, S. Patel, A.M. Strack, D.E. MacIntyre and L.P. Shearman Yanan Zhang, Marcus Brackeen, Anne CONFORMATIONALLY-CONSTRAINED 4 Gilliam, Herbert Seltzman 8.45 ANALOGS OF SR141716 and Brian Thomas Session 2. Receptor Structure and Signal Transduction ¾ Chairs: Drs. Ruth Ross and Allyn Howlett Itai Bab, Joseph Tam, Orr Ofek, Catherine Ledent, Ester Fride, Yankel Gabet, Ralph INVOLVEMENT OF CB1 SIGNALLING 9.00 Müller, Andreas Zimmer, Ken Mackie, IN BONE REMODELLING 5 Raphael Mechoulam and Esther Shohami Sharon Anavi-Goffer, Daniel Fleischer, Dow P. Hurst, Diane L. Lynch, Judy Barnett-Norris, HELIX 8 LEUCINE OF CB1 9.15 Shanping Shi, Deborah L. Lewis, Somnath CANNABINOID RECEPTOR PROMOTES 6 Mukhopadhyay, Allyn C. Howlett, SELECTIVE G PROTEIN COUPLING Patricia H. Reggio and Mary E. Abood Sergio Oddi, Monica Bari, Filomena Fezza, LIPID RAFTS, CB2 RECEPTOR Valeria Gasperi, Paola Spagnuolo, Nicoletta SIGNALING AND METABOLISM OF 9.30 Pasquariello, Alessandro Finazzi-Agrò 2-ARACHIDONOYL-GLYCEROL IN 7 and Mauro Maccarrone HUMAN IMMUNE CELLS i CANNABIDIOL IS AN INVERSE AGONIST Adèle Thomas, Gemma Baillie, Alexander AND EXHIBITS UNEXPECTEDLY HIGH 9.45 Phillips, Ruth Ross and Roger Pertwee POTENCY AS AN ANTAGONIST AT MOUSE 8 BRAIN CB1 AND HUMAN CB2 RECEPTORS Ruth A. Ross, Gemma L. Baillie, Cherry Alexander, Emma Baillie, Lisa Gauson, Sarah ALLOSTERIC MODULATION OF THE 10.00 Robertson, Lesley A. Stevenson, Kirsty CANNABINOID CB1 RECEPTOR: NOVEL 9 Muirhead, Laurent Trembleau ALLOSTERIC MODULATORS and Roger G. Pertwee CB1 CANNABINOID RECEPTORS Allyn Howlett, Jenelle Jones MEDIATE TRANSLOCATION OF NO- 10.15 and Derek Norford SENSITIVE GUANYLYL CYCLASE IN 10 NEURONAL CELLS 10.30 - 11.00 Coffee Break RAPID RECEPTOR DESENSITIZATION Christopher Kearn, Giovanna Cacciola, MODULATES CANNABINOID 11.00 Tanya Daigle and Ken Mackie RECEPTOR ACTIVATION OF P42/P44 11 MAP KINASE THE EFFECTS OF CHRONIC 11.15 Chris Breivogel and Vanita Puri CANNABINOIDS IN 12 BETA-ARRESTIN2 -/- MICE CELLULAR SIGNALING PROPERTIES OF Neta Rimmerman, Heather Bradshaw, THE NEWLY IDENTIFIED FATTY ACID 11.30 AMIDE N-PALMITOYL GLYCINE 13 David O’Dell and J. Michael Walker FOUND IN RAT CENTRAL NERVOUS SYSTEM AND SKIN Patricia Reggio, Dow Hurst, Diane Lynch, CB1 L7.60I AND L7.60F MUTATIONS RESULT IN CONFORMATIONAL CHANGES IN HELIX Judy Norris, Sharon Anavi-Goffer 11.45 8 R7.56(400)-K7.58(402) ELBOW AND 14 and Mary Abood INTRACELLULAR FACE REGIONS OF CB1 12.00 - 12.15 Free Time 12.15 - 13.45 Lunch Session 3. Bioactive Lipids & Analytical Lipidology ¾ Chairs: Drs. Rao Rapaka and Heather Bradshaw MECHANISMS IN THE BIOSYNTHESIS George Kunos 13.45 OF CRITICAL LIPIDS UPDATE ON NEW ENDOGENOUS Raphael Mechoulam 14.00 LIPID LIGANDS LIPIDOMIC APPROACHES TO THE 14.15 J. Michael Walker IDENTIFICATION OF NOVEL, 15 ENDOGENOUS FATTY ACYL AMIDES Mauro Maccarrone, Anna Fiori, Monica Bari, Filippo Granata, Valeria Gasperi, M. ANANDAMIDE TRANSPORT ACROSS 14.30 Egle De Stefano, Alessandro Finazzi-Agrò THE BLOOD-BRAIN BARRIER 16 and Roberto Strom ANALYTICAL PROTEOMICS & FISHING Alexandros Makriyannis 14.45 FOR THE PHARMACOPHORE "VANILLIPIDOMICS": AN UPDATE ON Vincenzo Di Marzo ENDOGENOUS LIPID LIGANDS OF 15.00 and Luciano De Petrocellis 17 VANILLOID RECEPTORS 15.15 Daniele Piomelli LIPIDOMICS: THEN AND NOW ii Coffee Break / Poster Session 15.30 - 17.30 Sessions # 2 and 4 Session 4. Biosynthesis and Inactivation of Endocannabinoids and Related Lipids ¾ Chairs: Drs. Sherrye Glaser and Nephi Stella Jenny Wang, David Woodward, Alex LACK OF EFFECT OF FATTY ACID AMIDE HYDROLASE (FAAH) INHIBITORS ON Kharlamb, Benjamin Cravatt, Giorgio Ortar 17.30 INTRAOCULAR PRESSURE IN 18 and Vincenzo Di Marzo “GLAUCOMATOUS” MONKEYS DOES THE INITIAL CELLULAR UPTAKE OF ANANDAMIDE SHOW Christopher Fowler and Lina Thors 17.45 TEMPERATURE-DEPENDENCY AND 19 SATURABILITY? IDENTIFICATION OF A NOVEL Nephi Stella 18.00 MONOACYLGLYCEROL LIPASE (MGL) 20 FAAH (-/-) MICE EXHIBIT NORMAL CB1 Andrew J. Thorpe, Joel, Schlosburg, RECEPTOR FUNCTION FOLLOWING Benjamin F. Cravatt, Billy R. Martin, Laura 18.15 ACUTE OR REPEATED 21 J. Sim-Selley and Aron H. Lichtman ADMINISTRATION OF CANNABINOIDS Heather Bradshaw, Sherry Shu-Jung Hu, NOVEL METABOLISM OF N- Neta Rimmerman, David O'Dell, Kim ARACHIDONOYL GLYCINE BY FATTY 18.30 Masuda, Benjamin Cravatt 22 ACID AMIDE HYDROLASE and J Michael Walker Bo Tan, Heather B. Bradshaw, David K. RAPID IDENTIFICATION OF NOVEL O'Dell, M. Francesca Monn, Y. William ENDOGENOUS FATTY ACYL AMIDES USING 18.45 Yu, Harini Srinivasan, Jocelyn F. Krey NANO-LC-MS/MS AND INFORMATION- 23 and J. Michael Walker DEPENDENT ACQUISITION 20.00 Dinner Notes: iii Day 2 Monday, June 26th Session 5. Neuronal Development ¾ Chairs: Drs. Tibor Harkany and Tiziana Rubino Paul Berghuis, Michela Matteoli, Ken NEURONAL GROWTH CONE GUIDANCE 8.00 Mackie and Tibor Harkany BY ENDOCANNABINOIDS 24 THE ACTIVATION OF CANNABINOID María Gómez, Mariluz Hernández, Ruth RECEPTORS DURING BRAIN Pazos, Rosa Tolón, Julián Romero 8.15 DEVELOPMENT INFLUENCES CELL 25 and Javier Fernández-Ruiz ADHESION MOLECULE L1 IN RATS Session 6. Nervous Function and Neuropsychiatric Disorders ¾ Chairs: Drs. Tibor Harkany and Tiziana Rubino FURTHER EVIDENCE FOR THE INVOLVEMENT OF CB2 CANNABINOID Emmanuel Onaivi and Hiroki Ishiguro 8.30 RECEPTORS IN DEPRESSION AND 26 SUBSTANCE ABUSE József Haller, Krisztina Soproni, Balázs CORRELATED SPECIES DIFFERENCES IN THE Varga, Beáta Németh, Éva Mikics, EFFECTS OF CANNABINOID LIGANDS ON 8.45 ANXIETY AND ON GABAERGIC / 27 Tamás F. Freund, Ferenc Mátyás GLUTAMATERGIC SYNAPTIC and Norbert Hájos TRANSMISSION NEUROANATOMICAL SITES AND Tiziana Rubino, Cinzia Guidali, Natalia BIOCHEMICAL CORRELATES Realini, Daniela Viganò, Chiara Castiglioni 9.00 UNDERLYING CANNABINOID 28 and Daniela Parolaro MODULATION OF ANXIETY CB1 RECEPTOR ANTAGONISTS IN THE 9.15 Aldemar Degroot and George Nomikos PHARMACOTHERAPY OF ACTIVE 29 AVOIDANCE RELATED ANXIETY INVOLVEMENT OF THE 5-HT1A Paola Fadda, Maria Scherma, Paola Salis, SEROTONERGIC RECEPTORS IN THE 9.30 Paola Mascia, Liana Fattore ANXIETY-LIKE EFFECTS INDUCED BY THE 30 and Walter Fratta
Load more

Recommended publications
  • Summary: Traditionally, Bioanalytical Laboratories Do Not Report Actual
    Summary: Traditionally, bioanalytical laboratories do not report actual concentrations for samples with results below the limit of quantification (BLQ) in pharmacokinetic studies. BLQ values are outside the method calibration range established during validation and no data are available to support the reliability of these values. However, ignoring BLQ data can contribute to bias and imprecision in model-based pharmacokinetic analyses. From this perspective, routine use of BLQ data would be advantageous. We would like to initiate an interdisciplinary debate on this important topic by summarising the current concepts and use of BLQ data by regulators, pharmacometricians and bioanalysts. Through introducing the limit of detection and evaluating its variability BLQ data could be released and utilized appropriately for pharmacokinetic research. Keywords: Lower limit of quantification (LLOQ) Below limit of quantification (BLQ) result Limit of detection (LoD) Pharmacokinetic (PK) Pharmacodynamics (PD) Introduction Studying the effects of drugs remains central to both medical research and clinical practice. Two key branches of pharmacological analysis are (i) pharmacokinetics (PK), including drug absorption, distribution, metabolism and elimination, and (ii) pharmacodynamics (PD), exploring the effects of drugs on the living organism, including efficacy and toxicity. In PK studies the samples are collected in an effort to map the drug concentration over time in the patient. For samples collected many hours post-dose drug concentrations may be low, yet can still provide valuable information on pharmacokinetic parameters such as clearance [1,2]. Similarly, in the case of biomarker PD studies, concentrations that are too low to quantify with a particular bioanalytical method may still provide useful information. Bioanalytical laboratories define the lowest concentration that can be quantified accurately by a method as the lower limit of quantification (LLOQ).
    [Show full text]
  • 5-HT2A/2C Receptor Modulation of Absence Seizures and Characterization of the GHB-Model
    5-HT2A/2C receptor modulation of absence seizures and characterization of the GHB-model A thesis submitted to Cardiff University for the degree of Doctor of Philosophy by Marcello Venzi (MSc) School of Biosciences, Cardiff University, October 2014 Chapter 1 Declaration and Statements This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of PhD . Signed ………………………………………… (candidate) Date ………………………… STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed ………………………………………… (candidate) Date ………………………… II Chapter 1 Summary Absence seizures (ASs) are non-convulsive epileptic events which are common in pediatric and juvenile epilepsies. They consist of EEG generalized spike-and-wave-discharges (SWDs) accompanied by an impairment of consciousness and are expressed within the thalamocortical network.
    [Show full text]
  • Case 2:14-Cv-05824-ES-JAD Document 1 Filed 09/18/14 Page 1 of 35 Pageid: 1
    Case 2:14-cv-05824-ES-JAD Document 1 Filed 09/18/14 Page 1 of 35 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza, Suite 1520 Newark, New Jersey 07102-5426 (973) 286-6700 [email protected] Attorneys for Plaintiff Jazz Pharmaceuticals, Inc. UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY JAZZ PHARMACEUTICALS, INC., Civil Action No. ____________________ Plaintiff, COMPLAINT FOR PATENT INFRINGEMENT v. PAR PHARMACEUTICAL, INC., (Filed Electronically) Defendant. Plaintiff Jazz Pharmaceuticals, Inc. (“Jazz Pharmaceuticals”), by its undersigned attorneys, for its Complaint against defendant Par Pharmaceutical, Inc. (“Par”), alleges as follows: Nature of the Action 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. §100, et seq., arising from Par’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”) seeking ® approval to commercially market a generic version of Jazz Pharmaceuticals’ XYREM drug product prior to the expiration of United States Patent No. 8,772,306 (“the ’306 patent” or “the patent-in-suit”) owned by Jazz Pharmaceuticals. Case 2:14-cv-05824-ES-JAD Document 1 Filed 09/18/14 Page 2 of 35 PageID: 2 The Parties 2. Plaintiff Jazz Pharmaceuticals is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 3180 Porter Drive, Palo Alto, California 94304. 3. On information and belief, defendant Par Pharmaceutical, Inc. is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 300 Tice Boulevard, Woodcliff Lake, New Jersey.
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]
  • Characterization of the GHB Withdrawal Syndrome
    Journal of Clinical Medicine Article Characterization of the GHB Withdrawal Syndrome Casper J. H. Wolf 1,2,3,* , Harmen Beurmanjer 3,4 , Boukje A. G. Dijkstra 3,4 , Alexander C. Geerlings 1 , Marcia Spoelder 2 , Judith R. Homberg 2 and Arnt F. A. Schellekens 1,3 1 Medical Center, Department of Psychiatry, Radboud University, 6525 GA Nijmegen, The Netherlands; [email protected] (A.C.G.); [email protected] (A.F.A.S.) 2 Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and Behaviour, Radboud University, 6525 EN, Nijmegen, The Netherlands; [email protected] (M.S.); [email protected] (J.R.H.) 3 Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), 6525 HR Nijmegen, The Netherlands; [email protected] (H.B.); [email protected] (B.A.G.D.) 4 Novadic-Kentron Addiction Care, 5261 LX Vught, The Netherlands * Correspondence: [email protected] Abstract: The gamma-hydroxybutyric acid (GHB) withdrawal syndrome can have a fulminant course, complicated by severe complications such as delirium or seizures. Detoxification by tapering with pharmaceutical GHB is a safe way to manage GHB withdrawal. However, a detailed description of the course of the GHB withdrawal syndrome is currently lacking. This study aimed to (1) describe the course of GHB withdrawal symptoms over time, (2) assess the association between vital signs and withdrawal symptoms, and (3) explore sex differences in GHB withdrawal. In this observational multicenter study, patients with GHB use disorder (n = 285) were tapered off with pharmaceutical GHB. The most reported subjective withdrawal symptoms (SWS) were related to cravings, fatigue, insomnia, sweating and feeling gloomy.
    [Show full text]
  • The Role of G Protein-Coupled Receptors (Gpcrs) and Calcium Signaling in Schizophrenia
    cells Review The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines Tomasz Boczek 1 , Joanna Mackiewicz 1 , Marta Sobolczyk 1 , Julia Wawrzyniak 1, Malwina Lisek 1, Bozena Ferenc 1, Feng Guo 2 and Ludmila Zylinska 1,* 1 Department of Molecular Neurochemistry, Faculty of Health Sciences, Medical University of Lodz, 92215 Lodz, Poland; [email protected] (T.B.); [email protected] (J.M.); [email protected] (M.S.); [email protected] (J.W.); [email protected] (M.L.); [email protected] (B.F.) 2 Department of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang 110122, China; [email protected] * Correspondence: [email protected] Abstract: Schizophrenia is a common debilitating disease characterized by continuous or relapsing episodes of psychosis. Although the molecular mechanisms underlying this psychiatric illness remain incompletely understood, a growing body of clinical, pharmacological, and genetic evidence suggests that G protein-coupled receptors (GPCRs) play a critical role in disease development, progression, and treatment. This pivotal role is further highlighted by the fact that GPCRs are the most common Citation: Boczek, T.; Mackiewicz, J.; targets for antipsychotic drugs. The GPCRs activation evokes slow synaptic transmission through 2+ Sobolczyk, M.; Wawrzyniak, J.; Lisek, several downstream pathways, many of them engaging intracellular Ca mobilization. Dysfunctions M.; Ferenc, B.; Guo, F.; Zylinska, L. of the neurotransmitter systems involving the action of GPCRs in the frontal and limbic-related The Role of G Protein-Coupled regions are likely to underly the complex picture that includes the whole spectrum of positive Receptors (GPCRs) and Calcium and negative schizophrenia symptoms.
    [Show full text]
  • Gamma-Hydroxybutyric Acid (GHB) Critical Review Report
    Gamma-hydroxybutyric acid (GHB) Critical Review Report Expert Committee on Drug Dependence Thirty-fifth Meeting Hammamet, Tunisia, 4-8 June 2012 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) 2 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) Acknowledgements This report has been drafted under the responsibility of the WHO Secretariat, Essential Medicines and Health Products, Medicines Access and Rational Use Unit. The WHO Secretariat would like to thank the following people for their contribution in producing this critical review report: Dr. Louis S. Harris, USA (literature review and drafting), Dr Caroline Bodenschatz (editing) and Mr Kamber Celebi, France (questionnaire report). 3 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) 4 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) Contents SUMMARY ............................................................................................................................... 7 1. Substance Identification ....................................................................................................... 9 A. International Non-proprietary Name (INN) .............................................................. 9 B. Chemical Abstract Service (CAS) Registry Number ................................................. 9 C. Other chemical names ............................................................................................... 9 D. Trade names .............................................................................................................
    [Show full text]
  • Acamprosate Axis 1 Class Glutamate
    acamprosate Axis 1 Class glutamate Relevant mechanism receptor antagonist Axis 2 and 3 see next page Axis 4 Efficacy Anti-craving in alcohol abstinence after detoxification. Side effects Nausea, diarrhoea; caution in pregnancy Axis 5 Indications (FDA or EMA approved, or as stated) Maintenance of abstinence in alcohol dependence Committee notes See next page for more detailed neurobiological description, references acamprosate Axis 2 Subclass Axis 3 Neurobiological description NMDA antagonist, GABA and glutamate modulator Neurotransmitter actions Preclinical Reduces the ethanol-induced dopamine response in N. Accumbens; promotes the release of taurine Clinical Glutamate level in anterior cingulate reduced (¹H-MRS) Brain circuits Preclinical Clinical Reduces cue-related brain activity in posterior cingulate cortex (fMRI) Physiological Preclinical Reduces ethanol consumption and ethanol withdrawal in dependent animals; may act as a “partial co-agonist” at NMDA receptors possibly via a spermidine site Clinical Glutamate level in anterior cingulate reduced (¹H-MRS) References agomelatine Axis 1 Class melatonin Bimodal Relevant mechanism receptor agonist Axis 2 and 3 see next page Axis 4 Efficacy Improves symptoms of depression and anxiety Side effects Rare cases of transient elevation of hepatic enzymes; little effect on sexual function Axis 5 Indications (FDA or EMA approved, or as stated) Major depressive disorder Committee notes See next page for more detailed neurobiological description, references agomelatine Axis 2 Subclass melatonin,
    [Show full text]
  • Number 11 November 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology
    Volume 1 - Number 1 May - September 1997 Volume 24 - Number 11 November 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. One main scope of the Atlas is to conjugate the scientific information provided by cytogenetics/molecular genetics to the clinical setting (diagnostics, prognostics and therapeutic design), another is to provide an encyclopedic knowledge in cancer genetics. The Atlas deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It presents structured review articles ("cards") on: 1- Genes, 2- Leukemias, 3- Solid tumors, 4- Cancer-prone diseases, and also 5- "Deep insights": more traditional review articles on the above subjects and on surrounding topics. It also present 6- Case reports in hematology and 7- Educational items in the various related topics for students in Medicine and in Sciences. The Atlas of Genetics
    [Show full text]
  • The Effect of Gamma-Hydroxybutyric Acid on Naloxone-Precipitated Opiate Withdrawal Marc I
    ELSEVIER The Effect of Gamma-Hydroxybutyric Acid on Naloxone-Precipitated Opiate Withdrawal Marc I. Rosen, M.D., H. Rowland Pearsall, M.D., Scott W. Woods, M.D., and Thomas R. Kosten, M.D. Because gamma-hydroxybutyric acid (GHB), a GABA produced no significant attenuation of multiple withdrawal metabolite, attenuated spontaneous opiate withdrawal in a measures except for hot-cold feelings. GHB pretreatment prior study, we studied GHB's effect on naloxone­ slightly accelerated respiration prior to naloxone. precipitated opiate withdrawal. Eight opiate-dependent Differences with prior studies may be due to (1) timing of inpatients were stabilized on the opioid levorphanol, 18 mg GHB administration (giving postwithdrawal in prior daily. After an initial acclimatization challenge, subjects studies), (2) direct reversal of GHB's anti-withdrawal underwent three double-blind challenges on consecutive effects by naloxone, or (3) differences between naloxone­ days. Pretreatment in a balanced randomization was with precipitated and spontaneous opiate withdrawal. either placebo, GHB, 15 mg/kg, or GHB, 30 mg/kg, followed [Neuropsychopharmacology 14:187-193, 1996) an hour later by intravenous naloxone, 0.4 mg/70 kg. GHB KEY WORDS: Gamma-hydroxybutyric acid; Opiate; (Schmidt et al. 1991), and GHB's presence principally in Withdrawal; Naloxone; Detoxification the synaptosome of cells (Maitre et al. 1983). GHB's ef­ fects on other neurotransmitter systems are complex Clonidine's utility in opiate detoxification is limited by (Snead 1977; Tunnicliff 1992). The dopaminergic effects side effects including hypotension (Rudd and Blaschke of GHB and GHB-receptor ligands have been character­ (1985) and lack of efficacy against subjective withdrawal ized as "neurolepticlike" based on their ability acutely symptoms (Jasinski et al.
    [Show full text]
  • Terminology and Information on Drugs Third Edition
    Terminology and Information on Drugs Third edition Terminology and Information on Drugs Third edition UNITED NATIONS NEW YORK, 2016 UNITED NATIONS PUBLICATION Sales No. E.16.XI.8 ISBN: 978-92-1-148287-4 eISBN: 978-92-1-057914-8 Original language: English © United Nations, March 2016. All rights reserved, worldwide The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Photographs: UNODC and Health Sciences Authority, Singapore. ACKNOWLEDGEMENTS UNODC’s Laboratory and Scientific Section (LSS), headed by Dr. Justice Tettey, wishes to express its appreciation and thanks to the following experts who participated in an expert group meeting and/or contributed to the development and review of this revision of Terminology and Information on Drugs: Dr. Heesun Chung Graduate School of Analytical Science and Technology (GRAST), South Korea Prof. Les Iversen Advisory Council on the Misuse of Drugs (ACMD), United Kingdom Dr. Wendy Lim Jong Lee Health Sciences Authority, Singapore Dr. Franco Tagliaro University of Verona, Italy Mr. Eleuterio Umpiérrez Faculty of Chemistry, Universidad de la República, Uruguay Mr. Scott Oulton DEA Office of Forensic Sciences, United States The preparation of this manual was coordinated by Dr. Conor Crean, Dr. Iphigenia Naidis and Ms. Susan Ifeagwu, staff of LSS.
    [Show full text]
  • Gene Section Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Gene Section Review XIAP (X-linked inhibitor of apoptosis) Catarina Sofia Reis Silva, Gabriel Henrique Barbosa, Paola Cristina Branco, Paula Christine Jimenez, João Agostinho Machado-Neto, Letícia Veras Costa-Lotufo Department of Pharmacology, Institute of Biomedical Sciences of the University of Sao Paulo, Sao Paulo, Brazil (CSMRS, PCB, JAMN, LVCL); Department of Marine Science, Institute of Marine Sciences, Federal University of Sao Paulo, Santos, Brazil (GHB, PCJ); [email protected], [email protected]. [email protected], [email protected], [email protected], [email protected] Published in Atlas Database: March 2020 Online updated version : http://AtlasGeneticsOncology.org/Genes/XIAPID796chXq25.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/70862/03-2020-XIAPID796chXq25.pdf DOI: 10.4267/2042/70862 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology Gastric cancer; Head and neck squamous cell Abstract carcinoma; Kidney cancer; Leukemia; Liver cancer; X-linked inhibitor of apoptosis (XIAP), also referred Lung cancer; Lymphoma; Medulloblastoma; to as BIRC4 or IAP3, is one of the most studied Melanoma; Multiple myeloma; Neuroblastoma; members among the proteins known as Inhibitors of Oral cancer; Osteosarcoma; Ovarian cancer; Apoptosis Proteins (IAPs). This protein family Pancreatic Cancer; Prostate cancer; Thyroid cancer; portrays its main role by preventing apoptotic cell death through direct or indirect inhibition of caspase Identity activity. All members of the IAPs carry at least one BIR domain in their structure, which are generally Other names responsible for caspase interaction.
    [Show full text]